Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
none appears on more than one
Michael F. MacLean, 60, is an experienced financial executive and independent director with over 35 years of strategic financial leadership in the biotechnology and life sciences industries. He currently serves as a director of Research Alliance Corporation III (NASDAQ: RACC), a healthcare-focused special purpose acquisition company sponsored by an affiliate of RA Capital Management, a leading life sciences investment firm with over $15 billion in regulatory assets under management. MacLean was appointed to the RACC board effective May 19, 2026, in connection with the company's $75 million IPO, and was named Chair of the Audit Committee as well as a member of both the Nominating Committee and the Compensation Committee. He holds 39,130 Class B founder shares, received in two tranches—30,000 shares in March 2026 and an additional 9,130 shares in May 2026. RACC completed its IPO on May 20, 2026, selling 7,500,000 Class A ordinary shares at $10.00 per share, with the full $75 million of net proceeds placed in a trust account for the benefit of public shareholders pending a business combination.
Prior to his role at RACC, MacLean served as Chief Financial Officer of Avidity Biosciences, bringing deep financial and operational expertise in the biotech sector. He has also been appointed as an Independent Director at CAMP4 Therapeutics Corp., a position he assumed in 2026, and serves as a Director at Verve Therapeutics. In a significant transaction, RACC announced a business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company focused on advancing antisense oligonucleotide therapy rugonersen for Angelman Syndrome, with MacLean slated to remain on the board of the combined company post-closing. His educational background includes attendance at the Boston College Carroll School of Management. Based in the Boston area, MacLean's career spans senior financial leadership roles across multiple publicly traded and private life sciences companies, and his board service reflects a track record of guiding biotechnology organizations through capital formation, public listings, and strategic transactions.
This record is keyed to SEC CIK 0001383731 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 11 institutional-holder rows on these vehicles, under 10 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.